Delivering quality therapy since 1901

Announcements

 

 

Richter and Allergan expanded their distribution and supply agreement for Levosert to Latin America1895<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2019.00000000000<p><strong>​</strong><span lang="EN-US"><strong>Gedeon Richter Plc. (hereinafter&#58; “Richter”) today announced that it has entered into a distribution and supply agreement with a wholly owned subsidiary of Allergan plc (hereinafter&#58; “Allergan”) to commercialize its levonorgestrel releasing Intrauterine System (IUS) in Latin American countries. The product is already marketed by Richter under the trademark of Levosert<sup>TM</sup> since 2011 in most of Europe through agreements established with Allergan.</strong></span></p>2019-02-11T23:00:00Z2/12/2019 7:35:31 AM51http://rgextend.richter.hu/en-US/investors/announcements/Pages/Forms/AllItems.aspxhtmlFalseaspx
Richter Group Report - 12 Months to December 20181952<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2019.000000000002019-02-06T23:00:00Z2/7/2019 8:32:51 AM530http://rgextend.richter.hu/en-US/investors/announcements/Pages/Forms/AllItems.aspxhtmlFalseaspx
Extraordinary Announcement1956<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2019.000000000002019-02-06T23:00:00Z2/7/2019 5:06:52 PM444http://rgextend.richter.hu/en-US/investors/announcements/Pages/Forms/AllItems.aspxhtmlFalseaspx
Richter and Pantarhei signed a license and supply agreement for commercialisation of a novel combined oral contraceptive1925<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2019.00000000000<p>​Gedeon Richter Plc. (hereinafter&#58; &quot;Richter&quot;) and Pantarhei Bioscience BV (hereinafter&#58; &quot;Pantarhei&quot;) today announced that they have entered into a license and supply agreement to commercialise Pantarhei's combined oral contraceptive (COC), containing 30 µg ethinyl estradiol, 150 µg levonorgestrel and 50 mg dehydroepiandrosterone (DHEA). The product is under development with successfully completed Phase II trials and is ready for further clinical studies to obtain marketing approval. The geographic scope of the agreement covers Europe, Russia, Latin America and Australia.</p>2019-02-03T23:00:00Z2/4/2019 7:13:54 AM134http://rgextend.richter.hu/en-US/investors/announcements/Pages/Forms/AllItems.aspxhtmlFalseaspx
Composition of share capital and voting rights 1878<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2019.000000000002019-01-31T23:00:00Z2/1/2019 11:20:23 AM41http://rgextend.richter.hu/en-US/investors/announcements/Pages/Forms/AllItems.aspxhtmlFalseaspx
Richter Announces Withdrawal of its Marketing Authorisation Application for Efgratin (biosimilar pegfilgrastim)1917<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2019.00000000000<p>​<font color="#000000"><font face="Arial"><span lang="DE" style="line-height&#58;115%;font-family&#58;&quot;arial&quot;,&quot;sans-serif&quot;;font-size&#58;11pt;">Gedeon Richter Plc. </span><span lang="EN-US" style="line-height&#58;115%;font-family&#58;&quot;arial&quot;,&quot;sans-serif&quot;;font-size&#58;11pt;">(“Richter”) announced today that it has withdrawn its Application for a Marketing Authorisation (MAA) from the European Medicines Agency (EMA) for Efgratin, its biosimilar pegfilgrastim.</span></font></font></p>2019-01-31T23:00:00Z2/1/2019 2:20:00 PM148http://rgextend.richter.hu/en-US/investors/announcements/Pages/Forms/AllItems.aspxhtmlFalseaspx
Change in the Executive Management of Gedeon Richter Plc.1085<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2019.000000000002019-01-10T23:00:00Z1/11/2019 4:06:14 PM161http://rgextend.richter.hu/en-US/investors/announcements/Pages/Forms/AllItems.aspxhtmlFalseaspx
Composition of share capital and voting rights337<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2019.000000000002019-01-01T23:00:00Z1/2/2019 11:52:28 AM118http://rgextend.richter.hu/en-US/investors/announcements/Pages/Forms/AllItems.aspxhtmlFalseaspx
Extraordinary Announcement338<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2019.000000000002019-01-01T23:00:00Z1/2/2019 12:15:33 PM1145http://rgextend.richter.hu/en-US/investors/announcements/Pages/Forms/AllItems.aspxhtmlFalseaspx
Extraordinary Announcement273<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2018.000000000002018-12-18T23:00:00Z12/19/2018 3:15:23 PM1216http://rgextend.richter.hu/en-US/investors/announcements/Pages/Forms/AllItems.aspxhtmlFalseaspx